Limited coverage criteria – deferiprone

Last updated on June 12, 2025

 

Return to Special Authority drug list 

Generic name

deferiprone

Strength & form

100 mg/mL oral solution
1000 mg tablet

Special Authority criteria

Approval period

Treatment of transfusion-dependent iron overload due to thalassemia syndromes, where iron chelation therapy is required, according to established criteria*, and when a Special Authority request is submitted by a hematologist

Initial request: 1 year

Renewal request: 1 year

Practitioner exemptions

  • None

Special notes

  • None

Special Authority request form(s)

* Click on the Special Authority Form below for full criteria: